Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease-Reference-Cited by-同舟云学术

Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease

Published:2022-01-17 Issue:3 Volume:55 Page:370-371
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Pollok Richard C. G.¹²^ORCID,Jayasooriya Nishani¹²^ORCID

Affiliation:

1. Department of Gastroenterology St George's University Hospitals NHS Foundation Trust London UK

2. Institute for Infection and Immunity St George’s University of London London UK

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16747

Reference10 articles.

1. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study;Zhao M;Aliment Pharmacol Ther,2021

2. Real‐world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy;Chen C;Inflamm Bowel Dis,2019

3. Introduction of anti‐TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population‐based interrupted time series study;Murthy SK;Gut,2020

4. The outcomes of emergency admissions with ulcerative colitis between 2007 and 2017 in England;King D;J Crohn’s Colitis,2020

5. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring;Syed N;Crohn’s Colitis 360,2020